Nov 11 (China Knowledge) - iPhase Pharma Service (IPS), a Contract Research Organization (CRO) founded by a group of professionals from US pharmaceutical and contract service industries, has recently expanded its laboratory services to include tobacco smoke and nicotine exposure testing in Beijing E-Town.
IPS, set up in 2008 in Beijing E-Town, a triple A rated industrial park, is the only laboratory that won a Certificate of Accreditation by the Institute for Global Tobacco Control of The Johns Hopkins University for nicotine filter laboratory analysis in China. IPS has conducted the testing of secondhand smoke exposure in more than 50 cities in China; and, accordingly, it has become an important source of research data for the country's smoke control studies.
IPS, founded by Dr. Liu Hongjun, a returnee from the U.S had successfully developed primary hepatocyte and liver microsomes with independent intellectual property rights.
Being an independent third-party laboratory, IPS, with an area of 1,200 square meters, is equipped with over 40 state-of-art medical instruments with a total value of nearly RMB 20 million, and is able to provide hundreds of analysis and testing in many fields. It is legally qualified to independently issue testing reports.
As the Chinese place more and more importance on toxic and harmful tobacco smoke that contains at least 69 cancerous substances the service is expected to enjoy exponential growth.
Besides tobacco smoke testing, IPS also conducts many other environmental monitoring such as water and air quality monitoring, and investigation of pollution sources.